<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007821</url>
  </required_header>
  <id_info>
    <org_study_id>A5356</org_study_id>
    <nct_id>NCT05007821</nct_id>
  </id_info>
  <brief_title>Linezolid Dosing Strategies in Drug-Resistant TB</brief_title>
  <official_title>A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination With a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy (how well the medicines work) and&#xD;
      tolerability (whether participants stop treatment because of side effects from a drug or&#xD;
      treatment) of an anti-TB treatment regimen that compares two doses of linezolid (LZD),&#xD;
      combined with bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ). This study will also&#xD;
      measure the level of these medicines in the participants' blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is currently no &quot;standard of care&quot; or single standardized treatment regimen recommended&#xD;
      for everyone with drug resistant-tuberculosis (DR- TB). Current DR-TB treatments may not be&#xD;
      well tolerated and can often have side effects. There is a need to identify drugs with enough&#xD;
      anti-TB activity (treatment against TB) and good safety profiles that can improve outcomes in&#xD;
      the treatment of DR-TB.&#xD;
&#xD;
      The main purpose of this study is to evaluate the efficacy and tolerability of a new shorter&#xD;
      course anti-TB treatment regimen that compares two dosing strategies of linezolid (LZD),&#xD;
      combined with bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ). As a secondary aim,&#xD;
      the study will also assess the safety (the level and type of side effects from a drug or&#xD;
      treatment) of the combination of these drugs.&#xD;
&#xD;
      Everyone in the study will take these drugs once a day for the entire treatment period: BDQ,&#xD;
      DLM, and CFZ. The difference between the two treatment groups in the study is in how&#xD;
      participants will take the fourth drug: LZD. Participants in group A will take one dose of&#xD;
      LZD once a day for the entire treatment period. Participants in group B will take a higher&#xD;
      dose of LZD once a day for 4 weeks and then continue taking that higher dose of LZD just&#xD;
      three times a week for the rest of the treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A5356 is a phase II, prospective, randomized, two-arm, open-label, multicenter clinical trial to evaluate the anti-tuberculosis (TB) activity, safety, and tolerability of an injectable-free short course regimen for treatment of multidrug-/rifampicin-resistant (MDR-/RR-), pre-extensively drug-resistant (pre-XDR-), and extensively drug-resistant (XDR-) TB comparing two dosing strategies of linezolid (LZD) combined with bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative probability of sputum culture conversion</measure>
    <time_frame>Up to 26 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative probability of permanent discontinuation of at least one anti-TB drug due to adverse events, intolerance, or death</measure>
    <time_frame>Up to 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of sputum culture conversion</measure>
    <time_frame>At week 8</time_frame>
    <description>Probability of sputum culture conversion in liquid media</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of sputum culture conversion</measure>
    <time_frame>At week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of sputum culture conversion</measure>
    <time_frame>At week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of sputum culture conversion</measure>
    <time_frame>At week 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of permanent discontinuation of LZD due to AEs, intolerance, or death; temporary discontinuation of LZD for any reason; and dose reduction of LZD</measure>
    <time_frame>Up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of treatment-related adverse events</measure>
    <time_frame>Up to 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of unfavorable TB treatment outcome</measure>
    <time_frame>At week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of unfavorable TB treatment outcome</measure>
    <time_frame>At week 38</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative probability of unfavorable TB treatment outcome</measure>
    <time_frame>At week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delamanid minimum plasma concentration (Cmin)</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delamanid maximum plasma concentration (Cmax)</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delamanid time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delamanid area under the concentration-time curve (AUC)</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delamanid apparent oral clearance (CL/F)</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linezolid minimum plasma concentration (Cmin)</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linezolid maximum plasma concentration (Cmax)</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linezolid time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linezolid area under the concentration-time curve (AUC)</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linezolid apparent oral clearance (CL/F)</measure>
    <time_frame>At week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of doses taken during the treatment period</measure>
    <time_frame>Up to 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <condition>Tuberculosis</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm A participants will take linezolid (LZD) once a day for the entire treatment period.&#xD;
Weeks 1-26: LZD 600 mg once daily (QD)&#xD;
Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD&#xD;
Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD&#xD;
Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everyone in the study will take bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ) once a day for the entire treatment period. Arm B participants will take a higher dose of linezolid (LZD) once a day for 4 weeks and then continue taking that higher dose of LZD just three times a week for the rest of the treatment period.&#xD;
Weeks 1-4: LZD 1200 mg once daily (QD)&#xD;
Weeks 5-26: LZD 1200 mg three times per week (TIW)&#xD;
Weeks 1-2: BDQ 200 mg QD + DLM 300 mg QD + CFZ 300 mg QD&#xD;
Weeks 3-8: BDQ 200 mg QD + DLM 300 mg QD + CFZ 100 mg QD&#xD;
Weeks 9-26: BDQ 100 mg QD + DLM 300 mg QD + CFZ 100 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid 600 mg</intervention_name>
    <description>One 600mg tablet taken orally once daily (QD) in the morning during weeks 1-26</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>LZD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid 1200 mg (QD)</intervention_name>
    <description>Two 600mg tablets taken orally once daily (QD) in the morning during weeks 1-4</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>LZD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid 1200 mg (TIW)</intervention_name>
    <description>Two 600mg tablets taken orally three times per week (TIW; Mon-Wed-Fri) in the morning during weeks 5-26</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>LZD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bedaquiline 200 mg</intervention_name>
    <description>Two 100mg tablets taken orally once daily in the morning during weeks 1-8</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>BDQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bedaquiline 100 mg</intervention_name>
    <description>One 100mg tablet taken orally once daily in the morning during weeks 9-26</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>BDQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delamanid 300 mg</intervention_name>
    <description>Six 50mg tablets taken orally once daily in the morning during weeks 1-26</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>DLM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine 300 mg</intervention_name>
    <description>Three 100mg capsules taken orally once daily in the morning during weeks 1-2</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>CFZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine 100 mg</intervention_name>
    <description>One 100mg capsule taken orally once daily in the morning during weeks 3-26</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>CFZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged greater than or equal to 18 years at screening.&#xD;
&#xD;
          2. Newly diagnosed pulmonary drug-resistant tuberculosis (DR-TB), with resistance to at&#xD;
             least rifampicin or rifampin (which is a drug used in the therapy of tuberculosis)&#xD;
             confirmed from a sputum specimen collected within 60 days prior to entry.&#xD;
&#xD;
          3. HIV-1 infection status documented as either absent or present.&#xD;
&#xD;
          4. For participants living with HIV, either currently on an antiretroviral therapy (ART)&#xD;
             regimen or willing and able to start ART within 30 days after entry.&#xD;
&#xD;
          5. Efavirenz or etravirine (drugs used to treat HIV) must be discontinued prior to a&#xD;
             participant's starting anti-TB medications. For participants on efavirenz or&#xD;
             etravirine, they must be willing and able to discontinue these at least 7 days prior&#xD;
             to initiating study TB medications.&#xD;
&#xD;
          6. For participants living with HIV, CD4+ cell (a type of white blood cell) count greater&#xD;
             than or equal to 50 cells/mm3 obtained within 60 days prior to study entry.&#xD;
&#xD;
          7. For females of reproductive potential, negative serum or urine pregnancy test within 7&#xD;
             days prior to entry.&#xD;
&#xD;
          8. Females of reproductive potential who are participating in sexual activity that could&#xD;
             lead to pregnancy must agree to use two of the following forms of birth control while&#xD;
             receiving TB study medications and for 30 days after stopping study medications:&#xD;
&#xD;
               -  Male or female condoms&#xD;
&#xD;
               -  Diaphragm or cervical cap (with spermicide, if available)&#xD;
&#xD;
               -  Intrauterine device (IUD) or intrauterine system (IUS)&#xD;
&#xD;
               -  Hormone-based birth control (e.g., oral contraceptives, Depo-Provera, NuvaRing,&#xD;
                  implants)&#xD;
&#xD;
          9. Appropriate laboratory values as determined by the study doctor obtained within 14&#xD;
             days prior to entry.&#xD;
&#xD;
         10. Karnofsky performance score (an assessment tool for functional impairment) greater&#xD;
             than or equal to 50 within 30 days prior to entry.&#xD;
&#xD;
         11. Ability and willingness of candidate and/or legal guardian/representative to provide&#xD;
             informed consent and meet requirements for the study.&#xD;
&#xD;
         12. Chest X-ray obtained within 30 days prior to entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documentation of clinically significant (as judged by the study doctor) active&#xD;
             infections (including HIV-related opportunistic infections) other than TB and HIV&#xD;
             requiring treatment within 30 days prior to entry.&#xD;
&#xD;
          2. Evidence of clinically significant (as judged by the study doctor) metabolic,&#xD;
             gastrointestinal, cardiovascular, musculoskeletal, ophthalmological, pulmonary,&#xD;
             neurological, psychiatric, endocrine diseases, malignancy, or other abnormalities&#xD;
             (other than the indication being studied) that would interfere with study medications&#xD;
             or procedures.&#xD;
&#xD;
          3. Inability to take oral medications.&#xD;
&#xD;
          4. Suspected or documented TB involving the central nervous system, clinically&#xD;
             significant renal TB or TB pericarditis, or current extrapulmonary TB involving other&#xD;
             organ systems that might interfere with study medications or procedures, as judged by&#xD;
             the study doctor.&#xD;
&#xD;
          5. Prior treatment with one or more of the study drugs at any time in the past for an&#xD;
             episode of DR-TB that is not the qualifying episode or treatment for more than 7&#xD;
             cumulative days with one or more of the study drugs within 30 days prior to entry for&#xD;
             the qualifying episode of DR-TB.&#xD;
&#xD;
          6. History of allergy or hypersensitivity to any of the study drugs or medications in the&#xD;
             same class as the study drugs.&#xD;
&#xD;
          7. Known or suspected current alcohol and/or drug abuse that is, in the opinion of the&#xD;
             study doctor, sufficient to compromise the safety and/or cooperation of the&#xD;
             participant.&#xD;
&#xD;
          8. Receipt of any investigational drugs within 60 days prior to entry.&#xD;
&#xD;
          9. Known history of prolonged QT syndrome (heart rhythm condition that can potentially&#xD;
             cause fast, chaotic heartbeats) or current prolonged QT interval on screening&#xD;
             electrocardiogram (a medical test that detects cardiac (heart) abnormalities).&#xD;
&#xD;
         10. Known history of clinically significant cardiac arrhythmia (a condition in which the&#xD;
             heart beats with an irregular or abnormal rhythm) requiring medication or clinically&#xD;
             significant electrocardiogram (ECG) abnormality, in the opinion of the study doctor,&#xD;
             within 60 days prior to entry.&#xD;
&#xD;
         11. Pregnancy or current breastfeeding, or intent to become pregnant and/or breastfeed&#xD;
             while on study treatment.&#xD;
&#xD;
         12. Current use of monoamine oxidase inhibitors (type of medication used to treat&#xD;
             depression) or use within 30 days prior to entry.&#xD;
&#xD;
         13. Current use of serotonergic agents including SSRI/SNRI antidepressants or prior use&#xD;
             within 30 days prior to entry.&#xD;
&#xD;
         14. Known history of optic neuropathy (damage to the optic nerve in your eye) of any grade&#xD;
             as diagnosed by an ophthalmologist.&#xD;
&#xD;
         15. Current peripheral neuropathy (when nerves are damaged or destroyed and can't send&#xD;
             messages from the brain and spinal cord to the muscles, skin and other parts of the&#xD;
             body) with severe paresthesias (&quot;pins and needles&quot;) and/or mild weakness or worse&#xD;
             (Grade â‰¥2.).&#xD;
&#xD;
         16. Weight less than 35 kg (77 lbs).&#xD;
&#xD;
         17. Currently taking other prohibited medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Constance A. Benson, MD</last_name>
    <phone>619-543-8080</phone>
    <email>cbenson@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesca Conradie, MD, DTM&amp;H</last_name>
    <phone>27-11-2768800</phone>
    <email>fconradie@witshealth.co.za</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gaborone CRS</name>
      <address>
        <city>Gaborone</city>
        <state>South-East District</state>
        <country>Botswana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tebogo J. Kakhu</last_name>
      <phone>267-3931353</phone>
      <email>tkakhu@bhp.org.bw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao CRS (Site ID: 12201)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>91850-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra W. Cardoso, MD</last_name>
      <phone>55-21-22707064</phone>
      <email>sandra.wagner@ipec.fiocruz.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra W. Cardoso, MD</last_name>
      <phone>55-21-22707064</phone>
      <email>sandra.wagner@ipec.fiocruz.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (Site ID: 31730)</name>
      <address>
        <city>Port-au-Prince</city>
        <zip>HT-6110</zip>
        <country>Haiti</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandy N. Nerette, MD</last_name>
      <phone>509-22222241</phone>
      <email>snerette@gheskio.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS (Site ID: 30022)</name>
      <address>
        <city>Port-au-Prince</city>
        <zip>HT-6110</zip>
        <country>Haiti</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cynthia Riviere, MD</last_name>
      <phone>509-22222241</phone>
      <email>criviere@gheskio.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Byramjee Jeejeebhoy Medical College (BJMC) CRS (Site ID: 31441)</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nishi Suryavanshi, PhD</last_name>
      <phone>91-98-23248979</phone>
      <email>nishi@jhumitpune.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moi University Clinical Research Center (MUCRC) CRS (Site ID: 12601)</name>
      <address>
        <city>Eldoret</city>
        <state>Rift Valley</state>
        <zip>30100</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priscilla C. Cheruiyot</last_name>
      <phone>254-532060850</phone>
      <email>pcchepkorir@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barranco CRS (Site ID: 11301)</name>
      <address>
        <city>Lima</city>
        <zip>15063</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis A. Limo, DDS, MPH</last_name>
      <phone>51-1-2067800</phone>
      <phone_ext>210</phone_ext>
      <email>llimo@impactaperu.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC) (Site ID: 31981)</name>
      <address>
        <city>Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maricelle S. Gler</last_name>
      <phone>63-9178230431</phone>
      <email>tarcelasg@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of the Witwatersrand Helen Joseph (WITS HJH) CRS (Site ID: 11101)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Reyneke</last_name>
      <phone>27-11-2768817</phone>
      <email>areyneke@witshealth.co.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Durban International CRS (Site ID: 11201)</name>
      <address>
        <city>Durban</city>
        <state>Kwa Zulu Natal</state>
        <zip>4052</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosie Mngqibisa, MBChB</last_name>
      <phone>27-31-2611093</phone>
      <email>mngqibisa@ecarefoundation.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rustenburg CRS (Site ID: 31684)</name>
      <address>
        <city>Rustenburg</city>
        <state>North West Province</state>
        <zip>0300</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tania Adonis</last_name>
      <phone>27-87-1351587</phone>
      <email>tadonis@auruminstitute.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cape Town Lung Institute (UCTLI) CRS (Site ID: 31792)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape Province</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catrien Drinkwater</last_name>
      <phone>27-21-4066850</phone>
      <email>catrien.drinkwater@uct.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South African Tuberculosis Vaccine Initiative (SATVI) CRS (Site ID: 31793)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape Province</state>
        <zip>7705</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Hikuam</last_name>
      <phone>27-21-4066228</phone>
      <email>chris.hikuam@uct.ac.za</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)</name>
      <address>
        <city>Pathum Wan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Parawee Thongpaeng</last_name>
      <phone>662-6523040</phone>
      <phone_ext>106</phone_ext>
      <email>parawee.t@hivnat.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Milton Park CRS (Site ID: 30313)</name>
      <address>
        <city>Milton Park</city>
        <state>Harare</state>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Mahachi, MSc, RN</last_name>
      <phone>263-24-2701356</phone>
      <email>rmahachi@uzchs-ctrc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>Brazil</country>
    <country>Haiti</country>
    <country>India</country>
    <country>Kenya</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Bedaquiline</mesh_term>
    <mesh_term>Diarylquinolines</mesh_term>
    <mesh_term>Clofazimine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in the publication, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.</ipd_time_frame>
    <ipd_access_criteria>With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.&#xD;
For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.&#xD;
By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group &quot;Data Request&quot; form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

